Venture Global

We are a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. In April 2011, the FDA approved our first product, Horizantâ„¢ (gabapentin enacarbil) Extended-Release Tablets. Our collaborator, GlaxoSmithKline (GSK), is currently promoting Horizant in the United States. We are also developing gabapentin enacarbil with Astellas Pharma Inc. in Japan and five Asian countries. XenoPort's product candidates are being developed for the potential treatment of neuropathic pain, spasticity ...


There are no scholarships at this time


There are no events at this time

Company Data on Venture Global
provided by Owler


Venture Global is hiring for these positions

Show me: All available jobs